Moderna picks up a $75M cash windfall as longtime collaborator Vertex signs up for a gene editing assault on cystic fibrosis
After nailing down the top drug franchise in cystic fibrosis, Vertex $VRTX is turning to the mRNA aficionados at Moderna $MRNA to use gene editing tech for a generation 2.0 attempt to master the disease. This is their 3rd pact together in 4 years as they jointly set their sights on the patients who are toughest to treat.
Researchers at Moderna and Vertex will now work together to develop lipid nanoparticles and mRNA to deliver gene editing tools to cells in the lung to spur production of functional cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.